Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Authors:
- 3 September 2004
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (10) , 691-698
Abstract
Breast cancer cells are generally resistant to induction of apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we demonstrate that both TRAIL-sensitive and TRAIL-resistant breast cancer cell lines can be efficiently killed by overexpression of the TRAIL receptor, death receptor 4 (DR4). The extent of cell death depended on the strength of the promoter driving DR4 expression. When driven by the strong CMV promoter, expression of DR4 killed over 90% of cells in five out of six cell lines tested in the absence of exogenous TRAIL. When driven by the relatively weak tumor-specific hTERT promoter, DR4 was less effective alone, but sensitized cells to killing by TRAIL. The extent of TRAIL sensitization depended on the magnitude of hTERT promoter activity. MCF-7 cells were relatively resistant to the action of DR4. We compared expression of the genes involved in transduction and execution of the death receptor-initiated apoptotic stimuli between MCF-7 and DR4-sensitive cell lines. We confirmed that in the panel of cell lines, MCF-7 was the only line deficient in expression of caspase 3. Bcl-2 and FLIP proteins, implicated in suppression of TRAIL-induced apoptosis, were expressed at a higher level.Keywords
This publication has 34 references indexed in Scilit:
- Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIPMolecular and Cellular Biology, 2003
- Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cellsOncogene, 2002
- Mutation analysis and mRNA expression of trail‐receptors in human breast cancerInternational Journal of Cancer, 2002
- Identification of a caspase 3‐independent role of pro‐apoptotic factor Bak in TNF‐α‐induced apoptosisFEBS Letters, 2002
- Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma CellsJournal of Biological Chemistry, 2002
- An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2002
- Ectopic Expression of Bcl-2 and Bcl-xL Inhibits Apoptosis Induced by TNF-Related Apoptosis-Inducing Ligand (TRAIL) Through Suppression of Caspases-8, 7, and 3 and BID Cleavage in Human Acute Myelogenous Leukemia Cell Line HL-60Journal of Interferon & Cytokine Research, 2002
- Selective Expression of FLIP in Malignant Melanocytic Skin LesionsJournal of Investigative Dermatology, 2001
- Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literatureProstate Cancer and Prostatic Diseases, 1999
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997